Alnylam Pharmaceuticals (ALNY) FCF Margin (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly FCF Margin came in at 22.62% in Q2 2026, up 769.0% on a YoY basis from 2.6% in Q2 2025, and up 442.51% quarter-over-quarter from 4.17% in Q1 2026.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) FCF Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has reported FCF Margin for 18 consecutive years, with 22.62% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin rose 769.0% year-over-year to 22.62%; the trailing twelve-month figure through Jun 2026 stood at 17.07% (up 2118.0% YoY), and the FY2025 full-year result was 12.53%, up 1443.0% from the prior year.
- FCF Margin rose to 22.62% in Q2 2026 per ALNY's latest filing, from 4.17% in the prior quarter.
- Across five years, FCF Margin topped out at 45.61% in Q3 2023 and bottomed at 430.94% in Q1 2025.
- Historically, FCF Margin has averaged 36.18% across 5 years, with a median of 13.87% in 2024.
- The sharpest annual moves came in 2025 and 2026: FCF Margin slumped 41183 bps in 2025, then soared 43511 bps in 2026.
- Over 5 years, FCF Margin stood at 45.85% in 2022, then surged by 78 bps to 10.26% in 2023, then tumbled by 71 bps to 17.49% in 2024, then soared by 173 bps to 12.79% in 2025, then surged by 77 bps to 22.62% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 22.62%, 4.17%, and 12.79% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 14.91% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -22.35% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 61.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.62% |
| Mar 31, 2026 | 4.17% |
| Dec 31, 2025 | 12.79% |
| Sep 30, 2025 | 27.13% |
| Jun 30, 2025 | 14.93% |
| Mar 31, 2025 | -430.94% |
| Dec 31, 2024 | -17.49% |
| Sep 30, 2024 | 7.89% |
| Jun 30, 2024 | 17.60% |
| Mar 31, 2024 | -19.11% |
| Dec 31, 2023 | -10.26% |
| Sep 30, 2023 | 45.61% |
| Jun 30, 2023 | -23.50% |
| Mar 31, 2023 | -56.49% |
| Dec 31, 2022 | -45.85% |
| Sep 30, 2022 | -49.86% |
| Jun 30, 2022 | -61.77% |
| Mar 31, 2022 | -88.65% |
| Dec 31, 2021 | -66.54% |
| Sep 30, 2021 | -85.33% |